Loading stock…

Mankind Pharma Limited (MANKIND) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Mankind Pharma Limited

MANKINDMarket cap $11BPrice $26.1

Country🇮🇳India

SectorHealthcare

IndustryPharmaceuticals

Manufactures and sells affordable generic medicines, condoms, and consumer health products across India, reaching millions through household names like Manforce and Prega News. It's India's fourth-largest pharma company by revenue, built on mass-market trust rather than niche specialty drugs.

In Bastion Portfolios?

52W Return-7%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+13%8

Revenue Forecast

Rev CAGR (1y)+9%6

Rev CAGR (3y)+12%7

Rev CAGR (5y)+12%8

Earnings Forecast

EPS Growth Y+1+20%8

EPS Growth Y+2+25%8

EPS Growth Y+3+17%8

Quality

Margins

EBIT Margin21%7

Net Income Margin14%7

Free Cash Flow Margin17%7

Debt

Net Debt/EBITDA1.06

Efficiency

ROE13%6

ROAna–

Earnings Stability77

GEAR+STRONG77

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)411

P/E Ratio (Forward 3y)302

P/BV6.33

EV Multiples

EV/EBITDA Fwd262

EV/EBIT Fwd332

Yield

Free Cash Flow Yield2.4%4

Dividend Yieldna–

Momentum

Short term

1 month return+7%10

3 month return-2%6

YTD return+13%7

Mid term

Price vs 52wHigh95%9

1 year return+0%5

Long term

3 year return+38%5

5 year return+75%7

Risk Shield

Price Risk

Beta0.39

Volatility26%8

Free Cash Flow

Free Cash Flow Margin17%7

Free Cash Flow Yield2.4%4

Quality

ROCE28%10

Earnings Stability77

Net Debt/EBITDA1.06

02Growth

Is it actually growing, and how fast?

MANKINDMankind Pharma

Revenue FY26$1.5B

GROWTH RATING↗

STRONG73 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+13%8

Revenue, next 1Y+9%6

Revenue, next 3Y, CAGR+12%7

Revenue, next 5Y, CAGR+12%8

EARNINGS FORECAST▾SCORE

EPS growth, FY27E+20%8

EPS growth, FY28E+25%8

EPS growth, FY29E+17%8

GROWTH ASSESSMENT

STRENGTHS

It out-grows 73% of companies worldwide.

Revenue grew 13%/yr over the last 3 years, ahead of 70% of companies worldwide.8/10

Revenue is set to grow 12%/yr over the next 3 years, ahead of most of the market.7/10

Revenue grew 13%/yr over the last 3 years and is set to keep growing around 12%/yr.

The runway holds up: revenue is set to grow 12%/yr over five years.8/10

Earnings are set to grow faster than sales (EPS about 20%/yr vs revenue 12%/yr), so margins should widen.

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower.

03Price Momentum

Is the market behind it right now?

MANKINDMankind Pharma

Total return Current−5.3%

Price return Current−5.3%

MOMENTUM RATING↗

STRONG74 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+7%10

3-month return-2%6

YTD return+13%7

MID & LONG-TERM▾SCORE

% of 52-week high95%9

1-year return+0%5

3-year return+38%5

5-year return+75%7

MOMENTUM ASSESSMENT

STRENGTHS

It's up 0.2% over the past year, now sitting right at its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+7%) and so far this year (+13%).

WATCH

Average long-term results. Multi-year returns are middling (+38% over three years and +75% over five), roughly average for the market.

Returns sit at the market level over three months (-2%).

WEAKNESSES

None flagged.

BOTTOM LINE

Fresh Momentum

Short-term returns are strong but the long track record is thin. Momentum is building — confirmation from longer horizons would strengthen the case.

04Value

Are you paying a fair price for it?

Stop guessing on Mankind Pharma Limited. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

MANKINDMankind Pharma

Revenue FY26$1.5B

GROWTH RATING↗

STRONG73 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+13%8

Revenue, next 1Y+9%6

Revenue, next 3Y, CAGR+12%7

Revenue, next 5Y, CAGR+12%8

EARNINGS FORECAST▾SCORE

EPS growth, FY27E+20%8

EPS growth, FY28E+25%8

EPS growth, FY29E+17%8

GROWTH ASSESSMENT

STRENGTHS

It out-grows 73% of companies worldwide.

Revenue grew 13%/yr over the last 3 years, ahead of 70% of companies worldwide.8/10

Revenue is set to grow 12%/yr over the next 3 years, ahead of most of the market.7/10

Revenue grew 13%/yr over the last 3 years and is set to keep growing around 12%/yr.

The runway holds up: revenue is set to grow 12%/yr over five years.8/10

Earnings are set to grow faster than sales (EPS about 20%/yr vs revenue 12%/yr), so margins should widen.

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower.

03Price Momentum

Is the market behind it right now?

MANKINDMankind Pharma

Total return Current−5.3%

Price return Current−5.3%

MOMENTUM RATING↗

STRONG74 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+7%10

3-month return-2%6

YTD return+13%7

MID & LONG-TERM▾SCORE

% of 52-week high95%9

1-year return+0%5

3-year return+38%5

5-year return+75%7

MOMENTUM ASSESSMENT

STRENGTHS

It's up 0.2% over the past year, now sitting right at its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+7%) and so far this year (+13%).

WATCH

Average long-term results. Multi-year returns are middling (+38% over three years and +75% over five), roughly average for the market.

Returns sit at the market level over three months (-2%).

WEAKNESSES

None flagged.

BOTTOM LINE

Fresh Momentum

Short-term returns are strong but the long track record is thin. Momentum is building — confirmation from longer horizons would strengthen the case.

04Value

Are you paying a fair price for it?

Stop guessing on Mankind Pharma Limited. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community